Quarterly Result31 Oct 2025, 01:09 pm
Strides Pharma Science Ltd Delivers Robust Q2FY26 with Highest Ever Quarterly EPS
AI Summary
Strides Pharma Science Ltd announced its consolidated financial results for the quarter (Q2FY26) and half year (H1FY26) ended September 30, 2025. The company reported a revenue of 12,208 million, a gross margin of 7,056 million, and an operational PAT of 1,403 million, representing a YoY growth of 4.6%, 14.6%, and 84.3% respectively. The net debt reduced sequentially by 469 million despite currency headwinds and ongoing capex investments. The company's focus on profitability enabled the gross margin growth of 15% YoY, and EBITDA growth of 25% YoY. The operational EPS stood at 15.2 for the quarter.
Key Highlights
- Revenue at 12,208 million, grew 4.6% YoY
- Gross margin improved to 57.8%, up 500bps YoY
- EBITDA grew 25.4% YoY to 2,316 million, EBITDA margin at 19.0%, grew 320bps YoY
- Operational PAT at 1,403 million, Grew 84.3% YoY
- Operational EPS at 15.2